Abstract:Dear Editor, We read the recent meta-analysis by Dai et al. on liver injury caused by oral anticoagulants with great interest. With the widespread use of direct oral anticoagulants (DOACs) in clinical practice for the prevention of thrombotic events, certain concerns have been raised with its risk of inducing liver injury. Such findings were not revealed in clinical trials, with a meta-analysis demonstrating no significant associations between DOAC use and liver injury. Specifically regarding edoxaban, the landmark ENGAGE AF-TIMI 48 trial found that hepatic events, as defined by AST or ALT ≥3× upper limit of normal or above with total bilirubin ≥2× upper limit of normal, were comparable among the warfarin, high-dose and low-dose edoxaban groups. However, the occurrence of drug-induced liver injury for DOACs has been reported by several case reports and series in post-market settings, and has been summarized by Liakoni et al. as early in 2015. These variations in results have led to investigations of drug-induced liver injury by individual DOACs in observational studies. Nevertheless, limited data are available for edoxaban, given its comparative late entry into the international market. Therefore, we conducted this territory-wide study to assess the risk of liver injury in edoxaban users who have no prior history of liver diseases. This study received approvals from Institutional Review Board of the University of Hong Kong—Hospital Authority Hong Kong West Cluster, and the Joint Chinese University of Hong Kong—Hospital Authority New Territories East Cluster Clinical Research Ethics Committee. The detailed methods are shown in the Supplementary Appendix. Among the 2107 edoxaban users from January 01, 2016 to December 31, 2019 initially identified, 894 patients were excluded for the following reasons: (1) prescriptions of other anticoagulants (n = 543); a prior diagnosis of liver disease (n = 16); prior liver injury (n = 335) (Figure 1). Finally, 1213 edoxaban users were included (Table 1, left), with 19 developing liver injury after its prescription, which corresponded to an incidence of 1.5% (Figure 2). Univariate Cox regression identified significant predictors of liver injury (Table 1, right), which were: older age (HR: 1.32, 95% CI: [1.03, 3.29], p = .006), prior hemorrhagic stroke (HR: 5.24, 95% CI: [1.53, 17.99], p = .009), and higher levels of creatinine (HR: 1.002, 95% CI: [1.000, 1.005], p = .021) and urea (HR: 1.10, 95% CI: [1.04, 1.16], p = .001). The main finding of this study is that there is a low rate of liver injury of 1.5% in patients receiving edoxaban therapy in Hong Kong. This extends previous findings by another local study, which reported an incidence of 1.8% for dabigatran, 2.1% for rivaroxaban, 2.5% for apixaban, with a pooled incidence rate of 2.0% for all three DOACs, as compared to 3.7% for warfarin. Edoxaban, similar to the other DOACs, has demonstrated at least non-inferiority compared to warfarin for stroke prevention in patients with atrial fibrillation. Our data provide further evidence regarding the safety of edoxaban specifically regarding hepatotoxicity. However, significant factors include advancing age, impaired renal function and prior haemorrhagic stroke. Therefore, this medication should be used in caution in such users, who should receive regular blood tests. Our findings should be validated in future observational cohort studies or clinical trials. Moreover, a follow-up analysis of the ENGAGE AF-TIMI 48 trial demonstrated that a history of liver disease did not significant affect the efficacy of safety of edoxaban compared to warfarin and the rates of hepatic adverse events were similar between edoxaban or warfarin users. Future observational studies should examine the efficacy and safety outcomes in this specific subgroup to complement findings from this important trial.

Clinical outcomes of edoxaban treatment without parenteral anticoagulation therapy for acute venous thromboembolism: Insight from the COMMAND VTE Registry-2

Edoxaban, Rivaroxaban or Apixaban for Cancer-Associated Venous Thromboembolism in the Real World: Insights from the COMMAND VTE Registry-2

Transition of management strategies and long-term outcomes in cancer-associated venous thromboembolism from the warfarin era to the direct oral anticoagulant era

The impact of renal function on clinical outcomes of patients with cancer-associated isolated distal deep vein thrombosis: Insights from the ONCO DVT study

Evaluation of acute thrombus regression effect of edoxaban for deep vein thrombosis in patients with cancer: a single-center prospective observational study

The initial high-dose versus maintenance-dose anticoagulation therapy with direct oral anticoagulants for cancer-associated venous thromboembolism: from the COMMAND VTE Registry-2

Periprocedural Edoxaban Management and Clinical Outcomes in Patients Undergoing Transcatheter Cardiovascular Procedures in the EMIT-AF/VTE Program

The effect of off-label use of reduced-dose direct oral anticoagulants therapy in the treatment of pulmonary embolism comparable to standard-dose therapy

Impact of Anemia on Clinical Outcomes of Patients With Cancer-Associated Isolated Distal Deep Vein Thrombosis Receiving Edoxaban - Insights From the ONCO DVT Study

Long-Term Efficacy and Safety of Direct Oral Anticoagulants at Reduced Doses in the Secondary Prevention of Venous Thromboembolism and Post-Thrombotic Syndrome

Safety and efficacy of direct oral anticoagulants in patients with chronic thromboembolic pulmonary hypertension

Anticoagulation in chronic thromboembolic pulmonary hypertension: A systematic review and meta-analysis

Direct Oral Anticoagulants in Antiphospholipid Syndrome-Associated Venous Thromboembolism: Real World Evidence

Edoxaban for 12 Versus 3 Months in Cancer-associated Isolated Distal Deep Vein Thrombosis According to Different Doses: Insights from the ONCO DVT study

Bleeding Risk and Mortality of Edoxaban: a Pooled Meta-Analysis of Randomized Controlled Trials.

Effectiveness of edoxaban in portal vein thrombosis associated with liver cirrhosis

Comparative analysis of vitamin K antagonists and direct oral anticoagulants for left ventricular thrombus management: a retrospective study utilising TriNetX

Comparative efficacy and safety of oral anticoagulants for the treatment of venous thromboembolism in the patients with different renal functions: a systematic review, pairwise and network meta-analysis

Efficacy and Safety of Direct Oral Anticoagulants for Acute Treatment of Venous Thromboembolism in Older Adults: A Network Meta-Analysis of Randomised Controlled Trials

The Effectiveness and Safety of Rivaroxaban and Edoxaban in the Treatment of Lower Extremity Deep Vein Thrombosis

Low Rates of Liver Injury in Edoxaban Users: Evidence from a Territory‐wide Observational Cohort Study